Autobio Diagnostics Co

Autobio Diagnostics Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Autobio Diagnostics Co (603658.SS) as of Oct 16, 2026 is 10.01 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 9.70 % — a change of 3.19% (higher).

EBIT/Assets

10.01 %

YoY

3.19%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Autobio Diagnostics Co is 2025 10.01 % . Operating Income to Assets Ratio (EBIT/Assets) of Autobio Diagnostics Co was 2024 9.70 % . It decreases by 3.19% higher compared to the previous year.

The Autobio Diagnostics Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
23.71 CNY
Jan 1, 2019
21.01 CNY
Jan 1, 2020
10.52 CNY
Jan 1, 2021
11.66 CNY
Jan 1, 2022
12.38 CNY
Jan 1, 2023
11.82 CNY
Jan 1, 2024
9.70 CNY
Jan 1, 2025
10.01 CNY
The Autobio Diagnostics Co EBIT/Assets history
YEAREBIT/AssetsYoY
10.01 %+3.19%
9.70 %-17.91%
11.82 %-4.51%
12.38 %+6.20%
11.66 %+10.75%
10.52 %-49.90%
21.01 %-11.41%
23.71 %+7.36%
22.09 %+1.99%
21.66 %-34.38%
33.00 %-7.63%
35.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Autobio Diagnostics Co Stock analysis

What does Autobio Diagnostics Co do? Autobio Diagnostics Co Ltd, listed on the Shanghai Stock Exchange under ticker 603658.SS, is a healthcare company based in Zhengzhou, China. The company specializes in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. With a workforce of 5,505 employees, Autobio Diagnostics went public on September 1, 2016. Its product portfolio includes immunodiagnostic reagents such as microplate chemiluminescence diagnostic reagents, enzyme-linked immunosorbent assay (ELISA) diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The company also offers microbiology detection products, including training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products encompass microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. Autobio Diagnostics primarily serves domestic markets within China, focusing on providing diagnostic solutions for healthcare applications. The company's headquarters is located in Zhengzhou, Henan Province, and it operates within the healthcare sector, specifically in the health care industry. Its website, https://www.autobio.com.cn/, provides further information on its services and products. Autobio Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autobio Diagnostics Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Autobio Diagnostics Co is 10.01 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Autobio Diagnostics Co changed from 9.70 % to 10.01 %, representing a 3.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Autobio Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Autobio Diagnostics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Autobio Diagnostics Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Autobio Diagnostics Co